6
Participants
Start Date
October 31, 2007
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
Imatinib
Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
Nilotinib (AMN107)
Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
St. Luke's Hospital and Health Network, Bethlehem
Johns Hopkins Hospital, Baltimore
Wake Forest University Health Sciences, Winston-Salem
Duke University Hospital, Durham
Vanderbilt University, Nashville
Jones Cancer Center, Germantown
Indiana Blood and Marrow Transplantation, Beech Grove
University of Michigan, Ann Arbor
Hematology Centers of Western Michigan, Grand Rapids
Holden Cancer Center, Iowa City
Northwestern Memorial Hospital, Chicago
The University of Chicago Medical Center, Chicago
Methodist Cancer Center, Omaha
University of Texas/MD Anderson Cancer Center, Houston
Rocky Mountain Cancer Center, Denver
Arizona Cancer Center, Tucson
Southern California Permanente Medical Group, Los Angeles
Southen California Permanente Medical Group, Woodland Hills
Southern California Permanente Medical Group, Panorama City
Southern California Permanente Medical Group, Baldwin Park
Southern California Permanente Medical Group, San Diego
Southern California Permanente Medical Group, Fontana
Southern California Permanente Medical Group, Riverside
Southern California Permanente Medical Group, Anaheim
Kaiser Permanente Medical Group, San Francisco
Kaiser Permanente Medical Group/South San Francisco Medical Center, South San Francisco
Kaiser Permanente Medical Group/Sacramento Medical Center, Sacramento
Kaiser Permanente Medical Group/Hayward Medical Center, Hayward
Kaiser Permanente Medical Group/Vallejo Medical Center, Vallejo
Kaiser Permanente Medical Group/Walnut Creek Medical Center, Walnut Creek
Kaiser Permanente Medical Group/Oakland Medical Center, Oakland
Kaiser Permanente Medical Group/Santa Clara Medical Office, Santa Clara
Kaiser Permanente Medical Group, San Jose
Oregon Health Sciences University, Portland
Swedish Cancer Institute, Seattle
The Cancer Center at Hackensack University Medical Center, Hackensack
Novartis Investigative Site, Darlinghurst
Novartis Investigative Site, Herston
Novartis Investigative Site, Liverpool
Novartis Investigative Site, Perth
Novartis Investigative Site, Prahran
Novartis Investigative Site, South Brisbane
Novartis Investigative Site, St Leonards
Novartis Investigative Site, Bruges
Novartis Investigative Site, Ghent
Novartis Investigative Site, Leuven
Novartis Investigative Site, Mannheim
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Olomouc
Novartis Investigative Site, Prague
Novartis Investigative Site, Berlin
Novartis Investigative Site, Düsseldorf
Novartis Investigative Site, Eisensach
Novartis Investigative Site, Firenze
Novartis Investigative Site, Greifswald
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Jena
Novartis Investigative Site, Kiel
Novartis Investigative Site, Leipzeg
Novartis Investigative Site, Postsdam
Novartis Investigative Site, Rostock
Novartis Investigative Site, Stuttgart
Novartis Investigative Site, Weiden
Novartis Investigative Site, Bologna
Novartis Investigative Site, Milan
Novartis Investigative Site, Napoli
Novartis Investigative Site, Orbassano
Novartis Investigative Site, Reggio Calabra
Novartis Investigative Site, Roma
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Oaska
Novartis Investigative Site, Tokyo
Novartis Investigative Site, Hwasun-Gun
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Madrid
Novartis Investigative Site, Salamanca
Novartis Investigative Site, Santiago de Compostela
Novartis Investigative Site, Valencia
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY